According to a presentation made at the annual meeting of the American College of Rheumatology in Philadelphia, a drug that was previously approved for treating non-Hodgkin’s B cell lymphoma and rheumatoid arthritis can prove effective for treating severe ANCA-associated vasculitis on the lines of cyclophosphamide, the current standard therapy.

The drug, Rituxan, works at least as well as cyclophosphamide.

In the study, patients were administered with steroids and randomized to receive either the standard treatment with cyclophosphamide or Rituxan at a dose of 75 mg/m2 weekly for four weeks.

From Sciencedaily.com:

“The reason this is a big deal is that this is a disease where people would come in and be told ‘listen, we are probably going to be able to get on top of your life-threatening disease by using cyclophosphamide, there is the potential for major side effects down the road from this drug,’” said Robert Spiera, M.D., an associate attending rheumatologist at Hospital for Special Surgery in New York. “This study provides strong evidence that Rituxan works as well as cyclophosphamide, at least in terms of getting patients into remission, and over that acute hump of being very ill. And, we can treat patients without the likelihood of causing infertility or causing secondary cancers, which have been a concern with the use of cyclophosphamide.”

Hospital for Special Surgery was one of nine centers involved in the Phase III trial that was led by Ulrich Specks, M.D., a professor of medicine in the Department of Pulmonary and Critical Care Medicine at the Mayo Clinic, and John Stone, M.D., MPH, director, Clinical Rheumatology, Massachusetts General Hospital.

Bookmark It

Hide Sites

Tags: cyclophosphamide, Rheumatoid arthritis, steroids, vasculitis

Posted in Steroid Cycles, Steroids and Anabolic Steroids, buy steroids, steroid nation